

When the next pandemic wave comes

– Challenges and possibilities in the viral vaccine development

IVA's Div. X: Biotechnology welcomes you to a seminar on September 2

In the last few years, several viral infections of pandemic character have spread over the world. In a globalized world, infections spread faster than before and all means to slow down and limit the spread must be mobilized. Parallel to this development, our understanding of the immune system, vaccine adjuvants and delivery systems is increasing rapidly. These advances, together with new insights into the molecular biology of important human pathogens, have opened the door for several new effective vaccine approaches. Can we sit back and feel safe when the next pandemic wave comes?

Welcome to a meeting with *Alexander von Gabain*, Intercell AG, *Gunilla Karlsson Hedestam*, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet and *Pontus Nauc ler*, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet.

Welcome!

Staffan Josephson
Chairman Div. X

Arvid S derh ll
Secretary Div. X



Registration and more information

- Date:** Thursday September 2, 2010, 17:00–19:00 followed by dinner
- Venue:** IVA's Conference Center, Grev Turegatan 16, Stockholm
- Registration:** Please register at IVA's webpage at www.iva.se/avd-x-20100902 by the August 26. The fee for dinner is 300 SEK, incl. 60 SEK tax, and is payable to the academy's bankgiro account 5108-2527. Please state code 5082 and your name as a reference. IVA's organizational number is 262000-1160. Participation in only the seminar is free of charge and open to all persons interested.
- More info:** Contact Arvid S derh ll, arvid.soderhall@iva.se or +46-(0)8-791 29 24.



Programme

17:00 Refreshments

17:15 **When the next pandemic wave comes – Challenges and possibilities in the viral vaccine development**

Alexander von Gabain, Intercell AG, introduces the theme: Scientific progress and new technology enable targeting novel microbial diseases. Where is the scientific horizon for adjuvants, antigens and delivery system? Alliances between academia, biotech, big pharma, and non-profit organizations move vaccine development forward.

Gunilla Karlsson Hedestam, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, goes deeper into the science: Vaccine development – from an empirical research discipline to knowledge-driven design, based on detailed information about pathogen structure and new insights into the functions of the human immune system. How do we target the most vital functions of viruses and stimulate immune responses that provide long-term protection?

Pontus Nauc ler, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet. This autumn a national vaccine program against cervical cancer is initiated in Sweden. We will learn more about eradication of cancer causing infections, HPV vaccination strategies and how to assess their effectiveness.

Discussion

19:00 Dinner

Moderator: *Hans Wigzell*



ROYAL SWEDISH ACADEMY OF ENGINEERING SCIENCES